UNLABELLED: The purpose of the study was to estimate the cost-effectiveness of balloon kyphoplasty compared to nonsurgical management and vertebroplasty for the treatment of hospitalised osteoporotic vertebral compression fractures in the UK. A cost-effectiveness model was constructed and used for analysis. Balloon kyphoplasty may be cost-effective compared to relevant alternatives. INTRODUCTION: The objective of this study was to estimate the cost-effectiveness of balloon kyphoplasty (BKP) for the treatment of patients hospitalised with acute osteoporotic vertebral compression fracture (OVCF) compared to percutaneous vertebroplasty (PVP) and nonsurgical management (NSM) in the UK. METHODS: A Markov simulation model was developed to evaluate treatment with BKP, NSM and PVP in patients with symptomatic OVCF. Data on health-related quality of life (HRQoL) with acute OVCF were derived from the FREE and VERTOS II randomised clinical trials (RCTs) and normalised to the NSM arm in the FREE trial. Estimated differences in mortality among the treatments and costs for NSM were obtained from the literature whereas procedure costs for BKP and PVP were obtained from three National Health Service hospitals. It was assumed that BKP and PVP reduced hospital length of stay by 6 days compared to NSM. RESULTS: The incremental cost-effectiveness ratio was estimated at Great Britain Pound Sterling (GBP) 2,706 per quality-adjusted life year (QALY) and GBP 15,982 per QALY compared to NSM and PVP, respectively. Sensitivity analysis showed that the cost-effectiveness of BKP vs. NSM was robust when mortality and HRQoL benefits with BKP were varied. The cost-effectiveness of BKP compared to PVP was particularly sensitive to changes in the mortality benefit. CONCLUSION: BKP may be a cost-effective strategy for the treatment of patients hospitalised with acute OVCF in the UK compared to NSM and PVP. Additional RCT data on the benefits of BKP and PVP compared to simulated sham surgery and further data on the mortality benefits with BKP compared to NSM and PVP would reduce uncertainty.
UNLABELLED: The purpose of the study was to estimate the cost-effectiveness of balloon kyphoplasty compared to nonsurgical management and vertebroplasty for the treatment of hospitalised osteoporotic vertebral compression fractures in the UK. A cost-effectiveness model was constructed and used for analysis. Balloon kyphoplasty may be cost-effective compared to relevant alternatives. INTRODUCTION: The objective of this study was to estimate the cost-effectiveness of balloon kyphoplasty (BKP) for the treatment of patients hospitalised with acute osteoporotic vertebral compression fracture (OVCF) compared to percutaneous vertebroplasty (PVP) and nonsurgical management (NSM) in the UK. METHODS: A Markov simulation model was developed to evaluate treatment with BKP, NSM and PVP in patients with symptomatic OVCF. Data on health-related quality of life (HRQoL) with acute OVCF were derived from the FREE and VERTOS II randomised clinical trials (RCTs) and normalised to the NSM arm in the FREE trial. Estimated differences in mortality among the treatments and costs for NSM were obtained from the literature whereas procedure costs for BKP and PVP were obtained from three National Health Service hospitals. It was assumed that BKP and PVP reduced hospital length of stay by 6 days compared to NSM. RESULTS: The incremental cost-effectiveness ratio was estimated at Great Britain Pound Sterling (GBP) 2,706 per quality-adjusted life year (QALY) and GBP 15,982 per QALY compared to NSM and PVP, respectively. Sensitivity analysis showed that the cost-effectiveness of BKP vs. NSM was robust when mortality and HRQoL benefits with BKP were varied. The cost-effectiveness of BKP compared to PVP was particularly sensitive to changes in the mortality benefit. CONCLUSION: BKP may be a cost-effective strategy for the treatment of patients hospitalised with acute OVCF in the UK compared to NSM and PVP. Additional RCT data on the benefits of BKP and PVP compared to simulated sham surgery and further data on the mortality benefits with BKP compared to NSM and PVP would reduce uncertainty.
Authors: J A Kanis; O Johnell; A Oden; I Sembo; I Redlund-Johnell; A Dawson; C De Laet; B Jonsson Journal: Osteoporos Int Date: 2000 Impact factor: 4.507
Authors: Mark Otto Baerlocher; Peter L Munk; David M Liu; George Tomlinson; Maziar Badii; Stephen T Kee; Chris T Loh; Brian W Hardy; Kieran J Murphy Journal: Radiology Date: 2010-06 Impact factor: 11.105
Authors: David F Kallmes; Jeffrey G Jarvik; Richard H Osborne; Bryan A Comstock; Margaret P Staples; Patrick J Heagerty; Judith A Turner; Rachelle Buchbinder Journal: Radiology Date: 2010-06 Impact factor: 11.105
Authors: Caroline A H Klazen; Paul N M Lohle; Jolanda de Vries; Frits H Jansen; Alexander V Tielbeek; Marion C Blonk; Alexander Venmans; Willem Jan J van Rooij; Marinus C Schoemaker; Job R Juttmann; Tjoen H Lo; Harald J J Verhaar; Yolanda van der Graaf; Kaspar J van Everdingen; Alex F Muller; Otto E H Elgersma; Dirk R Halkema; Hendrik Fransen; Xavier Janssens; Erik Buskens; Willem P Th M Mali Journal: Lancet Date: 2010-08-09 Impact factor: 79.321
Authors: Steven Boonen; Jan Van Meirhaeghe; Leonard Bastian; Steven R Cummings; Jonas Ranstam; John B Tillman; Richard Eastell; Karen Talmadge; Douglas Wardlaw Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: F Borgström; D P Beall; S Berven; S Boonen; S Christie; D F Kallmes; J A Kanis; G Olafsson; A J Singer; K Åkesson Journal: Osteoporos Int Date: 2014-11-08 Impact factor: 4.507
Authors: Salvatore Masala; Andrea Magrini; Amedeo Taglieri; Giovanni Nano; Antonio Chiaravalloti; Eros Calabria; Roberta Di Trapano; Antonio Pietroiusti; Giovanni Simonetti Journal: Eur Radiol Date: 2014-04-18 Impact factor: 5.315
Authors: Farzad Omidi-Kashani; Ebrahim Ghayem Hasankhani; Mohammad H Ebrahimzadeh; Amir Reza Kachooei; Mohammad Hasani; Ali Moradi Journal: Arch Bone Jt Surg Date: 2013-09-15